The safety and immunogenicity of NVSI-06-08 as a heterologous booster dose in adults previously vaccinated with BBIBP-CorV
Researchers assessed the safety profile and immunogenicity of a heterologous NVSI-06-08 boost against SARS-CoV-2 variants in individuals doubly vaccinated with the inactivated vaccine BBIBP-CorV.